Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 5Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 22Thoracic 3Genitourinary 2Sarcoma 1Head & Neck 1Gynecologic 1CNS 1Breast 1

Conditions

Urinary Bladder Neoplasms 2Cone Dystrophy 3 1

Interventions

Docetaxel 69pembrolizumab 48Prednisone 43Nivolumab 40enzalutamide 38Gemcitabine 37Sunitinib 36Cyclophosphamide 29Radiotherapy 26Magnetic Resonance Spectroscopy 26Leuprolide 25Abiraterone Acetate 25Sorafenib 23Everolimus 23Cisplatin 23bicalutamide 19atezolizumab 18Carboplatin 18Bevacizumab 18avelumab 17Radiosurgery 17Goserelin 17Interleukin-2 16abiraterone 15fludarabine 14Doxorubicin 14olaparib 13durvalumab 13cabozantinib 13acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Panitumumab × Genitourinary × Clear all
NCT01916109 2016-02-12

Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
4 enrolled 6 charts
Genitourinary

Cone Dystrophy 3, Urinary Bladder Neoplasms

NCT01374789 2015-06-03

PURO

WiSP Wissenschaftlicher Service Pharma GmbH

Phase 2 Terminated
2 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡